{"title":"Erythropoietin recapitulates ultrasound-assessed hemodynamic and morphological features of hypoxia-induced pulmonary hypertension in mice","authors":"Ghina Bouabout , Julien Becker , Emilie Peter-Thiebaut , Mégane Denu , Hugues Jacobs , Benoit Petit Demoulière , Yann Herault , Laurent Monassier","doi":"10.1016/j.acvd.2025.03.015","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Pulmonary hypertension is characterized by increased pulmonary vascular resistances leading to right ventricular failure. Chronic hypoxia is a risk factor for PH. End-stage renal disease patients with chronic haemodialysis have increased risk of PH. Most of these are treated with erythropoietin (EPO) because of anaemia. Involvement EPO as causative of PH in controversial.</div></div><div><h3>Objective</h3><div>We investigated if an EPO treatment could reproduce hemodynamic and morphologic features of hypoxia-induced PH and whether endothelial progenitor cells mobilized in PH due to hypoxia, could be involved in EPO-induced PH.</div></div><div><h3>Method</h3><div>The first group of mice was treated with EPO for 2 and 4 weeks and the 2nd group of hypoxia (10%) was exposed during 2 and 4 weeks. Blood analysis, heart and valves remodeling and function were assessed by high frequency echocardiography (Vevo3100 from Visual sonics) using a linear MS440 and MS500 probe. Isovolumetric relaxation and contraction time were recorded with a pulsed-Doppler window placed at the tip of the leaflets valves and right ventricle strain was also evaluated. Blood pressure and heart rate were recorded. Right ventricular pressure, heart and lung histology and blood circulating endothelial progenitor cells were assessed after 2 weeks.</div></div><div><h3>Results</h3><div>The EPO treatment for 2 weeks and 4 weeks and hypoxia induce PH with an important increase in pulmonary and right ventricular pressure and RV/LV<!--> <!-->+<!--> <!-->septum size attested by pulmonary and peripheral vein pressure increases compared to normoxia animals. Similarly, the treatment with EPO or hypoxia in mice significantly alters the inferior vena cava (IVC) pulsatility index with a decrease in inspiratory fractional shortening. EPO and hypoxia groups show right ventricle hypertrophy as attested by an increased in RV/LV<!--> <!-->+<!--> <!-->septum weight ratio and pulmonary artery remodeling increased pulmonary wall vessel thickening of vessels with a diameter below 3–4<!--> <!-->μm (pre-acinar and intra-acinar pulmonary vessels) with an elastic fibrosis of alveolar vessels wall. EPO provoked an increase in the blood mobilization of endothelial progenitor cells at a similar extent than hypoxia.</div></div><div><h3>Conclusion</h3><div>EPO recapitulates hemodynamic features of hypoxia-induced pulmonary hypertension in mice when hematocrit is increased over the physiological range. Nevertheless a pharmacological effect not linked to hematopoiesis is discussed.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 6","pages":"Page S178"},"PeriodicalIF":2.3000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Cardiovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S187521362500110X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Pulmonary hypertension is characterized by increased pulmonary vascular resistances leading to right ventricular failure. Chronic hypoxia is a risk factor for PH. End-stage renal disease patients with chronic haemodialysis have increased risk of PH. Most of these are treated with erythropoietin (EPO) because of anaemia. Involvement EPO as causative of PH in controversial.
Objective
We investigated if an EPO treatment could reproduce hemodynamic and morphologic features of hypoxia-induced PH and whether endothelial progenitor cells mobilized in PH due to hypoxia, could be involved in EPO-induced PH.
Method
The first group of mice was treated with EPO for 2 and 4 weeks and the 2nd group of hypoxia (10%) was exposed during 2 and 4 weeks. Blood analysis, heart and valves remodeling and function were assessed by high frequency echocardiography (Vevo3100 from Visual sonics) using a linear MS440 and MS500 probe. Isovolumetric relaxation and contraction time were recorded with a pulsed-Doppler window placed at the tip of the leaflets valves and right ventricle strain was also evaluated. Blood pressure and heart rate were recorded. Right ventricular pressure, heart and lung histology and blood circulating endothelial progenitor cells were assessed after 2 weeks.
Results
The EPO treatment for 2 weeks and 4 weeks and hypoxia induce PH with an important increase in pulmonary and right ventricular pressure and RV/LV + septum size attested by pulmonary and peripheral vein pressure increases compared to normoxia animals. Similarly, the treatment with EPO or hypoxia in mice significantly alters the inferior vena cava (IVC) pulsatility index with a decrease in inspiratory fractional shortening. EPO and hypoxia groups show right ventricle hypertrophy as attested by an increased in RV/LV + septum weight ratio and pulmonary artery remodeling increased pulmonary wall vessel thickening of vessels with a diameter below 3–4 μm (pre-acinar and intra-acinar pulmonary vessels) with an elastic fibrosis of alveolar vessels wall. EPO provoked an increase in the blood mobilization of endothelial progenitor cells at a similar extent than hypoxia.
Conclusion
EPO recapitulates hemodynamic features of hypoxia-induced pulmonary hypertension in mice when hematocrit is increased over the physiological range. Nevertheless a pharmacological effect not linked to hematopoiesis is discussed.
期刊介绍:
The Journal publishes original peer-reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches, review articles and editorials. Topics covered include coronary artery and valve diseases, interventional and pediatric cardiology, cardiovascular surgery, cardiomyopathy and heart failure, arrhythmias and stimulation, cardiovascular imaging, vascular medicine and hypertension, epidemiology and risk factors, and large multicenter studies. Archives of Cardiovascular Diseases also publishes abstracts of papers presented at the annual sessions of the Journées Européennes de la Société Française de Cardiologie and the guidelines edited by the French Society of Cardiology.